Semaglutide GLP-1 is typically prescribed at higher doses than liraglutide
Conclusion: Meeting the moment The GLP-1 market is expanding rapidlyand so is the pressure on manufacturers to scale quickly
It drastically reduces the medication's effectiveness
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
Remember, the goal isnt just to lose weightits to build a healthier, more muscular body
Shapely FAQs We navigate insurance on your behalf and are able to work with the vast majority of insurance companies to get cost-effective access to GLP-1 medications like Mounjaro and Wegovy